|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.18 USD | -0.22% |
|
-5.53% | +26.19% |
| 07-14 | Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing | MT |
| 07-07 | RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating | MT |
Business description: Cytokinetics, Incorporated
Number of employees: 673
Sales by Activity: Cytokinetics, Incorporated
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M |
Geographical breakdown of sales: Cytokinetics, Incorporated
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M |
Executive Committee: Cytokinetics, Incorporated
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 62 | 31/12/2006 |
Sung Lee
DFI | Director of Finance/CFO | 55 | 07/05/2024 |
Fady Malik
CTO | Chief Tech/Sci/R&D Officer | 61 | 12/11/2015 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2019 |
Eric Brown
COO | Chief Operating Officer | - | 28/02/2018 |
Composition of the Board of Directors: Cytokinetics, Incorporated
| Director | Title | Age | Since |
|---|---|---|---|
Robert Blum
BRD | Director/Board Member | 62 | 31/12/2006 |
John Henderson
CHM | Chairman | 81 | 07/04/2022 |
Wendell Wierenga
BRD | Director/Board Member | 78 | 08/02/2011 |
B. Parshall
BRD | Director/Board Member | 72 | 06/02/2013 |
Edward Kaye
BRD | Director/Board Member | 76 | 19/05/2016 |
Nancy Wysenski
BRD | Director/Board Member | 68 | 19/11/2020 |
Muna Bhanji
BRD | Director/Board Member | 63 | 16/02/2021 |
| Director/Board Member | 65 | 07/04/2022 | |
Robert Landry
BRD | Director/Board Member | 62 | 09/02/2025 |
James Daly
BRD | Director/Board Member | 64 | 18/08/2025 |
Company details: Cytokinetics, Incorporated
Cytokinetics, Inc.
350 Oyster Point Boulevard
94080, South San Francisco
+650 624 3000
http://www.cytokinetics.com
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.22% | -5.53% | +115.36% | +138.49% | 10.89B | |
| +0.24% | -1.54% | +52.85% | +60.31% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.32% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +413.12% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -16.17% | 23.13B | |
| -5.95% | -2.58% | +29.53% | -7.67% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -31.21% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +291.24% | 15.2B | |
| -6.91% | -5.83% | +25.17% | +636.97% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +186.18% | 14.06B | |
| Average | -2.52% | -2.92% | +48.03% | +174.46% | 24.44B | |
| Weighted average by Cap. | -2.69% | -2.50% | +42.92% | +137.84% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CYTK Stock
- Company Cytokinetics, Incorporated
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition